S

Shanghai Aohua Photoelectricity Endoscope Co Ltd
SSE:688212

Watchlist Manager
Shanghai Aohua Photoelectricity Endoscope Co Ltd
SSE:688212
Watchlist
Price: 49.98 CNY 4.1% Market Closed
Market Cap: 6.7B CNY

Profitability Summary

Shanghai Aohua Photoelectricity Endoscope Co Ltd's profitability score is 45/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

45/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Shanghai Aohua Photoelectricity Endoscope Co Ltd

Revenue
749.5m CNY
Cost of Revenue
-247.1m CNY
Gross Profit
502.5m CNY
Operating Expenses
-490.4m CNY
Operating Income
12.1m CNY
Other Expenses
8.9m CNY
Net Income
21m CNY

Margins Comparison
Shanghai Aohua Photoelectricity Endoscope Co Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CN
Shanghai Aohua Photoelectricity Endoscope Co Ltd
SSE:688212
6.7B CNY
67%
2%
3%
US
Abbott Laboratories
NYSE:ABT
232.3B USD
56%
17%
32%
US
Intuitive Surgical Inc
NASDAQ:ISRG
190.7B USD
67%
28%
28%
US
Boston Scientific Corp
NYSE:BSX
154.3B USD
69%
19%
12%
US
Stryker Corp
NYSE:SYK
146.5B USD
65%
22%
12%
IE
Medtronic PLC
NYSE:MDT
106.4B USD
66%
19%
13%
DE
Siemens Healthineers AG
XETRA:SHL
52.1B EUR
38%
13%
9%
US
Becton Dickinson and Co
NYSE:BDX
47.1B USD
45%
13%
7%
US
Edwards Lifesciences Corp
NYSE:EW
44.2B USD
79%
28%
75%
US
IDEXX Laboratories Inc
NASDAQ:IDXX
38.7B USD
61%
29%
23%
CN
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
269.7B CNY
61%
34%
31%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Shanghai Aohua Photoelectricity Endoscope Co Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CN
Shanghai Aohua Photoelectricity Endoscope Co Ltd
SSE:688212
6.7B CNY
2%
1%
1%
3%
US
Abbott Laboratories
NYSE:ABT
232.3B USD
31%
18%
12%
21%
US
Intuitive Surgical Inc
NASDAQ:ISRG
190.7B USD
16%
14%
16%
23%
US
Boston Scientific Corp
NYSE:BSX
154.3B USD
10%
5%
10%
8%
US
Stryker Corp
NYSE:SYK
146.5B USD
14%
7%
15%
11%
IE
Medtronic PLC
NYSE:MDT
106.4B USD
8%
5%
8%
7%
DE
Siemens Healthineers AG
XETRA:SHL
52.1B EUR
11%
4%
8%
5%
US
Becton Dickinson and Co
NYSE:BDX
47.1B USD
6%
3%
6%
5%
US
Edwards Lifesciences Corp
NYSE:EW
44.2B USD
49%
37%
15%
18%
US
IDEXX Laboratories Inc
NASDAQ:IDXX
38.7B USD
59%
27%
51%
32%
CN
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
269.7B CNY
31%
21%
28%
34%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less